News | September 27, 2024
Alembic receives USFDA final approval for Paliperidone ER tablets
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Subscribe To Our Newsletter & Stay Updated
